AstraZeneca’s vaccine would reduce serious forms by 94% and would also be very effective in elderly patients.
- The risk of hospitalization of vaccinated people over the age of 80 would have decreased by 81% on average.
- The side effects observed after vaccination would be mild, temporary and mainly present in young patients.
Severe forms of Covid-19 decreased by 94% in Scottish patients who received the AstraZeneca vaccine. It is the result of a preliminary study from the University of Edinburgh. This percentage is 85% for people vaccinated with the Pfizer product. To arrive at these results, the researchers analyzed the social security data of the 20% of the population of this country who were vaccinated. The other lesson from the Scottish scientists is that the vaccines from AstraZeneca and Pfizer would also be effective in older patients. Indeed, the risk of hospitalization of vaccinated people over 80 years of age would have fallen by 81% on average. And this, for the Covid-19 and the British variant.
“You have to take some common sense measures”
In France, city doctors now have the right to administer the AstraZeneca vaccine to patients between 50 and 64 years old, with comorbidities. According to Professor Alain Fischer, coordinator of the vaccination campaign in France, the tolerance data of this one would also be reassuring: the side effects observed after vaccination would be mild, temporary and especially present in young patients. Regarding this AstraZeneca vaccine, Alain Fischer estimated, on February 18 at the microphone of Europe 1, that: “In terms of tolerance (…) in young subjects it more often causes a syndrome, say, flu-like” and add: “it is necessary to take some common sense measures: stagger the dates of vaccination, take paracetamol for young people.”
Pr Alain Fischer on the effectiveness of AstraZeneca: “It is not a second-class vaccine. It gives very good rates of effectiveness. It is a good vaccine.”#Europe1 pic.twitter.com/gN5Gey1DBa
— Europe 1 ???????????? (@Europe1) February 18, 2021
AstraZeneca does not commit to the delivery of its vaccines
Last January, AstraZeneca announced a delay in the delivery of its doses to the European Union for the first quarter of 2021: only 40 million doses out of the 120 million that had been promised. A blow for all the member countries who were also counting on this delivery to achieve their vaccination objectives. Pascal Canfin, MEP and President of the Committee on the Environment, Public Health and Food Safety, was the guest ofEuropean 1 this Friday, February 26. The day before, he had interviewed seven laboratory bosses about their vaccine production. He assured that the boss of the AstraZeneca laboratory, Pascal Soriot, “was still unable to formally commit to the fact that its laboratory will respect the commitments made for the second quarter, namely to deliver 180 million doses over March-April-May, and therefore enough to vaccinate at least 90 million Europeans“. So far, 2,712,800 people have received the first dose of one of the vaccines in France, according to Public health France.
.